Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas

Journal of Pathology

Volumn 181, Issue 2, 1997, Pages 140-145

  Bukholm, I K ^a   Nesland, J M ^a,d   Karesen R ^b   Jacobsen, U ^c   Borresen A L ^a,e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c Buskerud Central Hospital   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e INSTITUTE OF CANCER RESEARCH   (Norway)

Author keywords

Breast carcinoma; Cell cycle growth arrest; Immunohistochemistry; p21; p53; TP53 gene

Indexed keywords

PROTEIN P21; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CELL CYCLE; DOWN REGULATION; FEMALE; GEL ELECTROPHORESIS; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0031017282     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199702)181:2<140::AID-PATH745>3.0.CO;2-A     Document Type: Article

References (24)

1. O'Connor PM, Kohn KW. A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells? (Review). Semin Cancer Biol 1992; 3: 409-416.
2. Smith ML, Furnace AJ Jr. Grenomic instability and the role of p53 mutations in cancer cells (Review). Curr Opin Oncol 1995; 7: 69-75.
3. Hartwell LH, Weinert TA, Checkpoints: controls that ensure the order of cell cycle events (Review). Science 1989; 246: 629-634.
4. O'Connor PM, Ferris DK, Hoffmann I, Jackman J, Draetta G, Kohn KW. Role of the cdc25C phosphatase in G2 arrest induced by nitrogen mustard. Proc Natl Acad Sci USA 1994; 91: 9480-9484.
5. Murray AW. Creative blocks: cell-cycle checkpoints and feedback controls [see comments] (Review). Nature 1992; 359: 599-604.
6. Kastan MB, Onyekwere O, Sidransks D, Vogelslein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
7. Andersen TI, Børresen AL. Alterations of the TP53 gene as a potential prognostic marker in breast carcinoma. Advantages of using constant denaturant gel electrophoresis in mutation detection. Diagn Mol Pathol 1995; 4: 203-211.
8. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Børresen AL. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 1993; 68: 540-548.
9. Lohmann D, Ruhri C, Sehmitt M, Graeff H, Hofler H. Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives. Diagn Mol Pathol 1993; 2: 36-41.
10. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW. Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-860.
11. Kastan MB, Zhan Q, el-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-597.
12. el-Deiry WAS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
13. Bhatia K, Fan S, Spangler G, et al. A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. Cancer Res 1995; 55: 1431- 1435.
14. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
15. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, el-Houseini ME. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 1994; 9: 3389-3396.
16. Fan S, el-Deiry WAS, Bae I, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994; 54: 5824-5830.
17. Girinsky T, Koumenis C, Graeber TG, Peehl DM, Giaccia AJ. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res 1995; 55: 3726-3731.
18. Namba H, Hara T, Tukazaki T, et al. Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells. Cancer Res 1995; 55: 2075-2080.
19. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
20. Beahr OH, Henson DE, Hutter RVP, Myers MH. Manual for Staging of Cancer. Philadelphia: J. P. Lippincott, 1988: 145.
21. Hsu SM, Raine L, Fanger H. A comparative study of the peroxidase- antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 1981; 75: 734-738.
22. Kunkel LM, Smith KD, Bover SH, et al. Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants. Proc Natl Acad Sci USA 1977; 74: 1245-1249.
23. Børresen AL, Hovig E, Smilh-Sørensen B, et al. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci USA 1991; 88: 8405-8409.
24. Gudas J, Nguyen H, Li T, Hill D, Cowan KH. Effects of cell cycle, wild-type p53 and DNA damage on p21 CIP1/Waf1 expression in human breast epithelial cells. Oncogene 1995; 11: 253-261.